| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Bryszewska, Maria
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (22/22 displayed)
- 2024Recent advances in multifunctional dendrimer‐based complexes for cancer treatmentcitations
- 2023Ruthenium metallodendrimer against triple-negative breast cancer in micecitations
- 2023Boron nitride embedded in chitosan hydrogel as a hydrophobic, promising metal-free, sustainable antibacterial materialcitations
- 2023Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Modelscitations
- 2023Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models
- 2023Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocolscitations
- 2023Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocolscitations
- 2023Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary studycitations
- 2022Heterofunctionalized polyphenolic dendrimers decorated with caffeic acid: Synthesis, characterization and antioxidant activitycitations
- 2021Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNAcitations
- 2020Copper (II) metallodendrimers combined with pro- apaoptotic siRNAs as a promising strategy against breast cancer cellscitations
- 2020Glucose-modified carbosilane dendrimers: Interaction with model membranes and human serum albumincitations
- 2019Immunoreactivity changes of human serum albumin and alpha-1-microglobulin induced by their interaction with dendrimerscitations
- 2019Dendrimers and hyperbranched structures for biomedical applicationscitations
- 2019Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drugcitations
- 2019Dendrimer for Templating the Growth of Porous Catechol-Coordinated Titanium Dioxide Frameworks: Toward Hemocompatible Nanomaterialscitations
- 2018Ruthenium dendrimers as carriers for anticancer siRNAcitations
- 2016Fourier transform infrared spectroscopy (FTIR) characterization of the interaction of anti-cancer photosensitizers with dendrimerscitations
- 2015Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological actioncitations
- 2013Dendrimers as Antiamyloidogenic Agents. Dendrimer-amyloid Aggregates Morphology and Cell Toxicitycitations
- 2013Characterization of Dendrimers and Their Interactions with Biomolecules for Medical use by Means of Electron Magnetic Resonancecitations
- 2013Natural and Synthetic Biomaterials as Composites of Advanced Drug Delivery Nano Systems (ADDNSS). Biomedical Applicationscitations
Places of action
| Organizations | Location | People |
|---|
article
Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocols
Abstract
One of the major limitations for the treatment of many diseases is an inability of drugs to cross the cell membrane barrier. Different kinds of carriers are being investigated to improve drug bioavailability. Among them, lipid or polymer-based systems are of special interest due to their biocompatibility. In our study, we combined dendritic and liposomal carriers and analysed the biochemical and biophysical properties of these formulations. Two preparation methods of Liposomal Locked-in Dendrimers (LLDs) systems have been established and compared. Carbosilane ruthenium metallodendrimer was complexed with an anti-cancer drug (doxorubicin) and locked in a liposomal structure, using both techniques. The LLDs systems formed by hydrophilic locking had more efficient transfection profiles and interacted with the erythrocyte membrane better than systems using the hydrophobic method. The results indicate these systems have improved transfection properties when compared to non-complexed components. The coating of dendrimers with lipids significantly reduced their hemotoxicity and cytotoxicity. The nanometric size, low polydispersity index and reduced positive zeta potential of such complexes made them attractive for future application in drug delivery. The formulations prepared by the hydrophobic locking protocol were not effective and will not be considered furthermore as prospective drug delivery systems. In contrast, the formulations formed by the hydrophilic loading method have shown promising results where the cytotoxicity of LLD systems with doxorubicin was more effective against cancer than normal cells.